Condition: Healthy Volunteer Male Subjects · Sponsor: Berlin-Chemie AG Menarini Group
The aim of this study is to evaluate the bioequivalence and safety of Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain), compared to Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets (Astellas Pharma Europe B.V., the Netherlands), after single dose administration in healthy adult male subjects under fasting conditions.
This description comes directly from the study's public registry record.
Kai Schumacher, MD · +49 (0)30 6707 · kaischumacher@berlin-chemie.de
Anja Pagenkopf · +49 6707 · apagenkopf@berlin-chemie.de
Always discuss trial participation with your own doctor first.
| "Tonus-Les" LLC | Yerevan, Ankuk Region, Armenia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07156916